Payment overview · 2025
General Payments
$492.95
23 reported records · 16 companies
Healthcare provider profile · identity verified
Scott David Lippe, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Gastroenterology · PARAMUS, NJ · NPI 1992766844
Verified facts
What the public records show
CMS Open Payments records show Scott David Lippe, MD received $492.95 in general payments during 2025 across 23 reported records.
Medtronic, Inc. accounted for 22.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Vraylar by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Tresiba by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$109.83 | 22.3% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $107.06 | 21.7% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.81 | 6.7% | 2 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $25.39 | 5.2% | 1 | 2025 |
| Braintree Laboratories, Inc. | Unresolved — no canonical attribution shown | $25.22 | 5.1% | 1 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $24.77 | 5.0% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $19.97 | 4.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $19.72 | 4.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.44 | 3.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.29 | 3.9% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $18.24 | 3.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.97 | 3.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.88 | 3.6% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $17.57 | 3.6% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $16.30 | 3.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $1.49 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $492.95 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $109.83 | 2 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $107.06 | 6 | 2025 |
Source payment records
|
|||||
| VELSIPITY Normalized: velsipity |
Drug | PFIZER INC. | $32.81 | 2 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $25.39 | 1 | 2025 |
Source payment records
|
|||||
| SUFLAVE Normalized: suflave |
Drug | Braintree Laboratories, Inc. | $25.22 | 1 | 2025 |
Source payment records
|
|||||
| SUTAB Normalized: sutab |
Drug | Braintree Laboratories, Inc. | $25.22 | 1 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $24.77 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $19.97 | 1 | 2025 |
Source payment records
|
|||||
| ENTYVIO Normalized: entyvio |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| IQIRVO Normalized: iqirvo |
Drug | Ipsen Biopharmaceuticals, Inc | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $1.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
173 | 15 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 318 | 96 |
| Lactulose | Lactulose | 303 | 53 |
| Famotidine | Famotidine | 220 | 62 |
| Atorvastatin Calcium | Atorvastatin Calcium | 198 | 29 |
| Eliquis | Apixaban | 173 | 15 |
| Levothyroxine Sodium | Levothyroxine Sodium | 173 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 168 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 20 |
| Amlodipine Besylate | Amlodipine Besylate | 135 | 21 |
| Metformin Hcl | Metformin Hcl | 130 | 21 |
| Mupirocin | Mupirocin | 130 | 15 |
| Gabapentin | Gabapentin | 127 | 18 |
| Clonazepam | Clonazepam | 111 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 111 | 14 |
| Benztropine Mesylate | Benztropine Mesylate | 108 | 13 |
| Januvia | Sitagliptin Phosphate | 108 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 105 | 25 |
| Losartan Potassium | Losartan Potassium | 97 | 17 |
| Santyl | Collagenase Clostridium Hist. | 96 | 12 |
| Divalproex Sodium | Divalproex Sodium | 95 | 13 |
| Furosemide | Furosemide | 84 | 13 |
| Finasteride | Finasteride | 81 | 12 |
| Sertraline Hcl | Sertraline Hcl | 81 | suppressed |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 80 | 78 |
| Potassium Chloride | Potassium Chloride | 79 | 12 |
| Tramadol Hcl | Tramadol Hcl | 79 | suppressed |
| Ozempic | Semaglutide | 78 | 19 |
| Alprazolam | Alprazolam | 73 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 73 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 72 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 72 | suppressed |
| Lisinopril | Lisinopril | 71 | 15 |
| Levetiracetam | Levetiracetam | 68 | suppressed |
| Mounjaro | Tirzepatide | 68 | suppressed |
| Omeprazole | Omeprazole | 67 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 13 |
| Simvastatin | Simvastatin | 64 | suppressed |
| Loxapine | Loxapine Succinate | 62 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 59 | 11 |
| Fentanyl | Fentanyl | 51 | suppressed |
| Baclofen | Baclofen | 49 | suppressed |
| Lorazepam | Lorazepam | 49 | suppressed |
| Xifaxan | Rifaximin | 48 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 47 | 13 |
| Diazepam | Diazepam | 45 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | 17 |
| Olanzapine | Olanzapine | 45 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 44 | suppressed |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Carvedilol | Carvedilol | 42 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 41 | suppressed |
| Ibuprofen | Ibuprofen | 41 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 41 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 40 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | suppressed |
| Linzess | Linaclotide | 39 | suppressed |
| Risperidone Er | Risperidone Microspheres | 37 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 36 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 35 | suppressed |
| Jardiance | Empagliflozin | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | 11 |
| Peg-3350 And Electrolytes | Peg3350/Sod Sulf,bicarb,cl/Kcl | 32 | 30 |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Clozapine | Clozapine | 31 | suppressed |
| Nystatin | Nystatin | 31 | 13 |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Novolog | Insulin Aspart | 30 | suppressed |
| Mesalamine Er | Mesalamine | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Haloperidol | Haloperidol | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Humira(Cf) Pen | Adalimumab | 26 | suppressed |
| Metronidazole | Metronidazole | 26 | 23 |
| Trulicity | Dulaglutide | 26 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 26 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Anastrozole | Anastrozole | 23 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Vraylar | Cariprazine Hcl | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 20 | suppressed |
| Lacosamide | Lacosamide | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Humalog | Insulin Lispro | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Tresiba | Insulin Degludec | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Scopolamine | Scopolamine | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 16 | suppressed |
| Budesonide Ec | Budesonide | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Insulin Degludec | Insulin Degludec | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 14 | suppressed |
| Novolin R | Insulin Regular, Human | 14 | suppressed |
| Peg 3350-Electrolyte | Sodium Chloride/Nahco3/Kcl/Peg | 14 | 14 |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 11 | suppressed |
| Gavilyte-C | Peg3350/Sod Sulf,bicarb,cl/Kcl | 11 | 11 |
| Humira Pen | Adalimumab | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Perphenazine | Perphenazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $492.95 · 23 records | Medtronic, Inc. | DUPIXENT, ENTYVIO, GIMOTI, IQIRVO, JAKAFI, MINIMED 780G, RINVOQ, SKYRIZI, SUFLAVE, SUTAB, TREMFYA, TZIELD, VELSIPITY, VOQUEZNA, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error